Propanc Biopharma Unveils Patents for Novel Cancer and Fibrosis Treatment
I'm PortAI, I can summarize articles.
Propanc Biopharma Inc. has submitted a request for a foreign filing license from Spain for two provisional patents on new methods to treat resistant cancer and fibrosis. These patents, developed with Spanish universities, will be filed with IP Australia and other global jurisdictions. The company plans a Phase 1b study of its lead product, PRP, in 2026 to explore its therapeutic applications. This expands Propanc's intellectual property, detailing PRP's use for chronic diseases like fibrosis. Further studies are planned, and scientific results are yet to be presented.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments